Evidence map›Paper›PMID 35145418›Full record

ArticleFrontiers in pharmacology2022

A Repurposed Drug Screen for Compounds Regulating Aquaporin 5 Stability in Lung Epithelial Cells.

John Villandre, Virginia White, Travis B Lear, Yanwen Chen, Ferhan Tuncer, Emily Vaiz, Beyza Tuncer, Karina Lockwood, Dan Camarco, Yuan Liu and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Aquaporin-5 Dynamic Regulation.International journal of molecular sciences · 2023
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

John VillandreDepartment of Medicine, Acute Lung Injury Center of Excellence, University of Pittsburgh, Pittsburgh, PA, United States.
Virginia WhiteAging Institute, University of Pittsburgh, Pittsburgh, PA, United States.
Travis B LearVascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, United States.
Yanwen ChenAging Institute, University of Pittsburgh, Pittsburgh, PA, United States.
Ferhan TuncerAging Institute, University of Pittsburgh, Pittsburgh, PA, United States.
Emily VaizAging Institute, University of Pittsburgh, Pittsburgh, PA, United States.
Beyza TuncerAging Institute, University of Pittsburgh, Pittsburgh, PA, United States.
Karina LockwoodAging Institute, University of Pittsburgh, Pittsburgh, PA, United States.
Dan CamarcoAging Institute, University of Pittsburgh, Pittsburgh, PA, United States.
Yuan LiuDepartment of Medicine, Acute Lung Injury Center of Excellence, University of Pittsburgh, Pittsburgh, PA, United States.
Bill B ChenDepartment of Medicine, Acute Lung Injury Center of Excellence, University of Pittsburgh, Pittsburgh, PA, United States.
John EvankovichDepartment of Medicine, Acute Lung Injury Center of Excellence, University of Pittsburgh, Pittsburgh, PA, United States.
Institute on Aging · USUniversity of Pittsburgh · USMcGowan Institute for Regenerative Medicine · US

Funding

Systematic Investigation of Protein Ubiquitination in ARDSR35HL139860 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHEN, BEIBEI · 2018 to 2024
$6.3M
Translational Pulmonary Vascular BiologyT32HL110849 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Sruti Shiva · 2012 to 2026
$5.0M
DCAF7/HDAC4/TFEB axis in acute lung injuryR01HL142777 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LIU, YUAN · 2018 to 2022
$2.4M
Role of Fbxo48-mediated AMPK proteostasis in the pathogenesis and treatment of NAFLDR01DK119627 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JURCZAK, MICHAEL J., LIU, YUAN · 2019 to 2023
$2.0M
Degradation of Toll-Like Receptor 8 by RNF216 in response to plasma MicroRNA’s – A Novel Mechanism Regulating Inflammation in Acute Lung InjuryK08HL144820 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI EVANKOVICH, JOHN W · 2019 to 2023
$810k
NHLBI NIH HHS K08 HL144820NHLBI NIH HHS R01 HL142777NHLBI NIH HHS R35 HL139860NHLBI NIH HHS T32 HL110849
6 · The paper itself

Abstract

Aquaporin 5 (AQP5) is expressed in several cell types in the lung and regulates water transport, which contributes to barrier function during injury and the composition of glandular secretions. Reduced AQP5 expression is associated with barrier dysfunction during acute lung injury, and strategies to enhance its expression are associated with favorable phenotypes. Thus, pharmacologically enhancing AQP5 expression could be beneficial. Here, we optimized a high-throughput assay designed to detect AQP5 abundance using a cell line stably expressing bioluminescent-tagged AQP5. We then screened a library of 1153 compounds composed of FDA-approved drugs for their effects on AQP5 abundance. We show compounds Niclosamide, Panobinostat, and Candesartan Celexitil increased AQP5 abundance, and show that Niclosamide has favorable cellular toxicity profiles. We determine that AQP5 levels are regulated in part by ubiquitination and proteasomal degradation in lung epithelial cells, and mechanistically Niclosamide increases AQP5 levels by reducing AQP5 ubiquitination and proteasomal degradation. Functionally, Niclosamide stabilized AQP5 levels in response to hypotonic stress, a stimulus known to reduce AQP5 levels. In complementary assays, Niclosamide increased endogenous AQP5 in both A549 cells and in primary, polarized human bronchial epithelial cells compared to control-treated cells. Further, we measured rapid cell volume changes in A549 cells in response to osmotic stress, an effect controlled by aquaporin channels. Niclosamide-treated A549 cell volume changes occurred more rapidly compared to control-treated cells, suggesting that increased Niclosamide-mediated increases in AQP5 expression affects functional water transport. Taken together, we describe a strategy to identify repurposed compounds for their effect on AQP5 protein abundance. We validated the effects of Niclosamide on endogenous AQP5 levels and in regulating cell-volume changes in response to tonicity changes. Our findings highlight a unique approach to screen for drug effects on protein abundance, and our workflow can be applied broadly to study compound effects on protein abundance in lung epithelial cells.

Indexed as

Aquaporin 5lung epithelial cellsNiclosamideproteasomerepurposed drugs

Identifiers

PMID35145418
PMCPMC8821664
OpenAlexW4225999326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.